Global Pharmaceutical Markets

Introduction

Abstract

This report:

• Reviews global markets for prescription and over-the-counter therapeutic drugs and forecasts sales through 2012.
• Analyzes epidemiological, technological, drug development, regulatory, and competitive factors expected to influence drug sales and offers a qualitative as well as quantitative picture of the world pharmaceutical market in 2012.
• Discusses epidemiology, treatment algorithms, and relevant major manufacturers for each indication, accompanied by an analysis of current sales, major trends and future sales within this indication. Indications include cardiovascular disease, cancer, diabetes, depression and anxiety, infectious diseases, and others. Drug classes selected for analysis include cholesterol and triglyceride reducers, anti-ulcerants, antidepressants, antirheumatic non-steroidals, antipsychotics, calcium antagonists, erythropoeitins, ACE inhibitors, selected anti-cancer therapeutics, and others.
• Covers novel therapeutic monoclonal antibodies, therapeutic vaccines, stem cell products, and engineered therapeutic foods. The report discusses both expected and alternative scenarios for selected drug classes.
• Includes market shares, competitive analysis, regulatory considerations, patent analyses, and complete company profiles.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study examines world pharmaceutical markets and provides pertinent information about sales and production of pharmaceutical products, as well as information about national healthcare systems and drug pricing policies. The report covers 24 countries in detail and provides links to relevant information. There are also profiles of larger pharmaceutical and biotechnology companies, complete with revenue histories.

Trends in government policies concerning drug pricing and reimbursement are examined. The report also makes predictions about countries whose pharmaceutical market growth is likely to grow radically in the next 5 years.

REASONS FOR DOING THE STUDY

Although the pharmaceutical industry remains one of the most profitable and stable industries in the world, several variables are forcing fundamental changes in its structure. They are:

• Increasing government-imposed price reductions in prices
• An increasing role of generic substitutes (especially in Europe)
• The emergence of bio-pharmaceuticals and the bio-omics revolution
• Increasing buyer power of third-party payers, government buyers, and health maintenance organizations
• Increased health awareness among patients and government buyers
• Changing suppliers-enhanced outsourcing, in-licensing, contract research, and manufacturing activities.
• Additionally, changing world demographics are influencing the pharmaceutical industry. They include population aging, declining research and development (R&D) productivity, and the General Agreements on Tariffs and Trade (GATT) and Trade Related Intellectual Property Rights (TRIPS).

AUDIENCE FOR THE REPORT

This report is directed at decision-makers in each industry segment, as well as at individuals and organizations considering investing in drug discovery or drug discovery technology. These people include, but are not limited to the following:

• Business development professionals
• Venture capitalists
• Merger and acquisition executives
• Market and product management professionals
• Chief scientists and technical officers
• Equipment manufacturers
• Reagent suppliers

SCOPE AND FORMAT

The scope of this study encompasses the major sectors of the world pharmaceutical industry and major geographical markets. BCC Research has analyzed the forces affecting the world pharmaceutical markets, determined their impact on the market demand and growth, and also presented the growth forecast over the next 5 years. Key forces include the increasing role of substitutes (generic pharmaceuticals), threat of new entrants (biopharmaceuticals), increasing role of buyers (governments, insurance, etc.), and changing suppliers.

BCC Research has provided the comprehensive analyses of the industry on the worldwide basis and also provided the detailed profiles for 25 leading pharmaceutical markets across the globe. For each of the geographical markets, we have presented the sector information, pharmaceutical distribution and pricing, and reimbursement and regulations. In a nutshell, the report provides the reader with a one-stop analysis of the worldwide pharmaceutical industry.

METHODOLOGY AND INFORMATION SOURCES

Market data and other information used in this report was gathered from interviews with individuals in the industry, as well as a thorough review of technology and markets gathered from secondary sources. These sources include company annual, 10K and 10Q reports, company literature, trade literature, trade associations, and online sources. Note that the author of this report is herself involved in the development of a compound for amyotrophic lateral sclerosis.

Projections were based on current and historical levels of funding and revenues, potential end users, likely unit prices and rates of consumption. Final projections are based on the analysis of information from primary and secondary sources. All currency conversions were made based on the average value of the dollar during the last month of the year in question. In some cases, data is provided in the original currency for readers wishing to make their own comparisons. An online currency converter was used for this purpose.[1] All forecasts are presented in year 2008 constant dollars.

Table of Contents

Table of Contents

• Global Pharmaceutical Markets

Chapter- 1: SUMMARY

• AGING POPULATIONS AND CHRONIC DISEASES
• OVERALL GLOBAL PHARMACEUTICAL MARKETS
• SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 ($ BILLIONS)
• SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, 2006-2013 ($ BILLIONS)

Chapter- 2: OVERVIEW

• BACKGROUND ON THE INDUSTRY
• RECENT HISTORY
• BENEFITS, PROBLEMS, AND REGULATION
• CHANGES IN THE INDUSTRY
• HEALTHCARE EXPENDITURES
  • TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)

Chapter- 3: THE PHARMACEUTICAL INDUSTRY

• TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 ($ BILLIONS)
• RESEARCH AND DEVELOPMENT EXPENDITURES
  • TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 ($ BILLIONS)
• SECTOR PERFORMANCE
• BRANDED PHARMACEUTICALS
  • TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

Chapter- 4: UNITED STATES

• INTRODUCTION
  • TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)
  • FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)
  • TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)
• THE U.S. HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURES IN THE U.S.
  • FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 ($ BILLIONS)
  • TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006
  • TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 ($ BILLIONS, %)
  • TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 ($ BILLIONS)
• COMMON HEALTH PROBLEMS IN THE U.S.
  • TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)
• SMOKING
• CANCER
  • TABLE 16 INVASIVE CANCER, U.S., 2004 (%)
  • TABLE 16 (CONTINUED)
  • TABLE 17 CANCER DEATHS, U.S., 2004 (%)
  • TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)
• HIV INFECTION
• GOVERNMENT REGULATIONS
• INTRODUCTION
• DRUG DISCOVERY
• Preclinical Testing and Submission of an IND
• CLINICAL TRIALS
• TIMELINE AND COSTS
• SUBMISSION OF AN NDA OR BLA
• POST-FDA APPROVAL
• NEW DRUG APPROVALS
  • FIGURE 3 NME APPROVALS, 1997-2007
  • FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007
  • TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007
• DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?
• BLOCKBUSTER DRUGS
  • TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008
• OTHER SUCCESSFUL THERAPEUTIC AGENTS
  • TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)
• IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY?
• PHARMACEUTICAL PRICING
• FACTORS AFFECTING DRUG PRICES
• PHARMACY BENEFIT MANAGERS (PBMS)
  • TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)
• Pharmacy Benefit Managers … (Continued)
• PHARMACEUTICAL FLOW FROM MANUFACTURER TO PATIENT
• PHARMACEUTICAL WHOLESALING
  • TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)
• PHARMACEUTICAL RETAILING
  • TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)
• EXPORT-IMPORT PROFILE
  • TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
  • TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.S.
  • TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN THE U.S.
• PHRMA, THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
• GPHA, GENERIC PHARMACEUTICAL ASSOCIATION
• CHPA (CONSUMER HEALTHCARE PRODUCTS ASSOCIATION)
• COMPANY PROFILES: UNITED STATES
• ABBOTT LABORATORIES
• BIOGEN IDEC
• AMGEN
• BRISTOL-MYERS SQUIBB
• FOREST LABORATORIES
• GENENTECH
• GENZYME
• JOHNSON & JOHNSON
• ELI LILLY AND COMPANY
• MERCK & CO. INC.
• PFIZER
• WYETH PHARMACEUTICALS
• TEVA PHARMACEUTICALS
• Teva North America

Chapter- 5: CANADA

• INTRODUCTION
  • TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)
  • FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)
  • TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)
• THE CANADIAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN CANADA
  • TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005
• COMMON HEALTH PROBLEMS IN CANADA
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE AND CANCER
• HIV INFECTION
• PHARMACEUTICAL PRICING
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN CANADA
  • TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
  • TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)
• IMPORTANT ORGANIZATIONS IN CANADA
• STATISTICS CANADA
• RX&D, CANADA' S RESEARCH-BASED PHARMACEUTICAL COMPANIES
• CGPA (CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION)
• NDMAC (THE NONPRESCRIPTION DRUG MANUFACTURERS ASSOCIATION OF CANADA)
• COMPANY PROFILES: CANADA
• ABBOTT LABORATORIES, LIMITED
• ACTELION
• ASTRAZENECA CANADA INC.
• BAYER, INC.
• BRISTOL-MYERS SQUIBB CANADA
• ELI LILLY CANADA INC.
• GLAXOSMITHKLINE INC.
• HOFFMANN-LA ROCHE LIMITED
• LUNDBECK CANADA INC.
• MERCK FROSST CANADA LTD.
• NOVARTIS PHARMACEUTICALS CANADA INC.
• PFIZER CANADA INC.
• PURDUE PHARMA (1956)
• SANOFI-AVENTIS CANADA
• SOLVAY PHARMA INC
• WYETH PHARMACEUTICALS
• Wyeth Pharmaceuticals (continued)

Chapter- 6: MEXICO

• INTRODUCTION
  • TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)
• THE MEXICAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN MEXICO
  • TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005
• COMMON HEALTH PROBLEMS IN MEXICO
• OBESITY AND RELATED CONDITIONS
• DIABETES: THE LEADING CAUSE OF DEATH
• HIV INFECTION
• PHARMACEUTICAL REGULATION AND PRICING
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN MEXICO
  • TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN MEXICO
• STATISTICS MEXICO: SISTEMAS NACIONALES ESTADÍSTICO Y DE INFORMACIÓN GEOGRÁFICA (SNEIG)
• AFAMELA (ASOCIACION DE FABRICANTES DE MEDICAMENTOS DE LIBRE ACCESO AC)
• AMIIF (ASOCIACIÓN MEXICANA DE INDUSTRIALES DE INVESTIGACIÓN FARMACÉUTIA A.C., MEXICAN ASSOCIATION OF PHARMACEUTICAL COMPANIES)
• CANIFARMA (CAMARA NACIONAL DE LA INDUSTRIA FARMACEUTICA)
• FIFARMA, THE LATIN AMERICAN FEDERATION OF THE PHARMACEUTICAL INDUSTRY
• ILAR (INDUSTRIO LATINOAERMICANA DE AUTOMEDICACION RESPONSABLE)

Chapter- 7: BRAZIL

• INTRODUCTION
  • TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN BRAZIL
• THE HEALTHCARE SYSTEM (MEDICARE)
• PHARMACEUTICAL PRICING
• HEALTH PROBLEMS IN BRAZIL
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN BRAZIL
• BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS

Chapter- 8: EUROPE

• HEALTHCARE IN EUROPE
• REIMBURSEMENT OF PHARMACEUTICALS
• POPULATION DEMOGRAPHICS IN EUROPE
• POPULATION GROWTH, MEDIAN AGE, AND LIFE EXPECTANCY
• EXCESS WEIGHT
• LIFE EXPECTANCY IN EUROPE
• PHARMACEUTICAL MARKETS IN EUROPE
  • TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 ($ BILLIONS)
• PROPRIETARY PRESCRIPTION MEDICATIONS (ALSO CALLED BRANDED MEDICATIONS AND ETHICAL PHARMACEUTICALS)
  • TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
• DATA EXCLUSIVITY
• GENERIC MEDICATIONS
  • TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
• GENERIC SMALL MOLECULES
• BIOSIMILARS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

Chapter- 9: FRANCE

• INTRODUCTION
  • TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
  • FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
• HEALTHCARE EXPENDITURE IN FRANCE
  • TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005
• COMMON HEALTH PROBLEMS IN FRANCE
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
  • TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)
• PHARMACEUTICAL PRICING
  • FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%)
  • FIGURE 7 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
  • FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER (OTC) MEDICATIONS IN FRANCE
  • TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
  • TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)
• EXPORT-IMPORT PROFILE
  • TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 ($ BILLIONS)
  • TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 ($ BILLIONS)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006-2007 (% SHARE)
• FRANCE' S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)
  • TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)
• IMPORTANT ORGANIZATIONS IN FRANCE
• INSEE (NATIONAL INSTITUTE FOR STATISTICS AND ECONOMIC STUDIES)
• LEEM, THE FRENCH PHARMACEUTICAL COMPANIES ASSOCIATION
• CSRP (SYNDICATE OF PHARMACEUTICAL DISTRIBUTORS:
• FRANCE ALZHEIMER:
• COMPANY PROFILES: FRANCE
• BIOGARAN
• CERP
• MERCK GENERIQUES
• SANDOZ: (SEE GERMANY)
• SANOFI-AVENTIS
• Sanofi-Aventis (Continued)

Chapter- 10: GERMANY

• INTRODUCTION
  • TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
  • TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
  • FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)
• THE GERMAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN GERMANY
  • TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005
• COMMON HEALTH PROBLEMS IN GERMANY
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
  • TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)
• PRICING AND REIMBURSEMENT OF PHARMACEUTICAL AGENTS
  • FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%)
  • FIGURE 11 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
  • TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006-2007 (% SHARE)
• GERMAN PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
  • TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
• IMPORTANT ORGANIZATIONS IN GERMANY
• DESTATIS (FEDERAL STATISTICAL OFFICE)
• GERMAN FEDERAL MINISTRY FOR EDUCATION AND RESEARCH
• DEUTSCHE DIABETES-UNION
• PHARMA PRIVAT
• BAH, BUNDESVERBAND DER ARZNEIMITTEL-HERSTELLER E.V.
• VFA, THE GERMAN ASSOCIATION OF RESEARCH-BASED PHARMACEUTICAL COMPANIES
• COMPANY PROFILES: GERMANY
• CELESIO AG
• MERCK KGAA
• SANDOZ
• STADA ARZNEIMITTEL AG

Chapter- 11: UNITED KINGDOM (U.K.)

• INTRODUCTION
  • TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)
  • FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)
  • TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)
• THE U.K. HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN THE U.K.
  • TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005
• COMMON HEALTH PROBLEMS IN THE U.K.
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
  • TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)
  • TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 ($ MILLIONS)
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN THE U.K. AND REVENUE BREAKDOWN
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
  • TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)
• GENERIC DRUGS
  • TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.K.
  • TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
  • TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)
• EXPORT-IMPORT PROFILE
  • TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 ($ BILLIONS)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF TOTAL MARKET)
• U.K.' S PHARMACEUTICAL EXPORTS AND IMPORTS IN POUNDS STERLING
  • TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)
• IMPORTANT ORGANIZATIONS IN THE U.K.
• NATIONAL STATISTICS U.K.
• ABPI, THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY
• THE BRITISH ASSOCIATION OF PHARMACEUTICAL WHOLESALERS (BAPW)
• COMPANY PROFILES: U.K.
• AAH PHARMACEUTICALS
• GLAXOSMITHKLINE (GSK)
• MAWDSLEY-BROOKS & CO. LTD.
• PHOENIX HEALTHCARE DISTRIBUTION, LTD.
• UNICHEM
• Unichem (Continued)

Chapter- 12: ITALY

• INTRODUCTION
  • TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)
  • FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)
• THE ITALIAN HEALTHCARE SYSTEM AND GROWTH DRIVERS
  • TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005
• COMMON HEALTH PROBLEMS IN ITALY
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN ITALY
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN ITALY
  • FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%)
  • FIGURE 15 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
  • TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)
• EXPORT-IMPORT PROFILE
  • TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 ($ BILLIONS, ROUNDED)
  • TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)
  • TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 ($ BILLIONS)
  • TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)
• ITALY' S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
  • TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
• IMPORTANT ORGANIZATIONS IN ITALY
• NATIONAL INSTITUTE FOR STATISTICS (ISTITUTO NAZIONALE DI STATISTICA)
• FARMINDUSTRIA, THE PHARMACEUTICAL MANUFACTURER' S ASSOCIATION OF ITALY
• ASSOGENERICI, THE ITALIAN NATIONAL ASSOCIATION OF GENERIC PHARMACEUTICALS

Chapter- 13: SPAIN

• INTRODUCTION
  • TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
  • FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
• THE SPANISH HEALTHCARE SYSTEM, PRICING, AND PHARMACEUTICAL GROWTH DRIVERS
• THE HEALTHCARE SYSTEM
  • TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005
• DRUG PRICING POLICIES
• COMMON HEALTH PROBLEMS IN SPAIN
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006
• GROWTH DRIVERS
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN SPAIN
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN SPAIN
  • FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%)
  • FIGURE 17 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ MILLIONS)
• EXPORT-IMPORT PROFILE
  • TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)
  • TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)
• IMPORTANT ORGANIZATIONS IN SPAIN
• NATIONAL STATISTICS INSTITUTE (INSTITUTO NACIONAL DE ESTADISTICA)
• FARMAINDUSTRIA, THE NATIONAL ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY IN SPAIN
• AESEG, THE SPANISH ASSOCIATION OF GENERIC PHARMACEUTICALS MANUFACTURERS
• ANEFP, THE NATIONALS ASSOCIATION OF OVER-THE-COUNTER MEDICATIONS
• CEAFA, CONFEDERACTION ESPANOLA DE FAMILIARES ENFERMOS DE ALZHEIMER' S Y OTRAS DEMENCIAS

Chapter- 14: SMALLER PHARMACEUTICAL MARKETS IN EUROPE

• GREECE
• INTRODUCTION
  • TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)
  • FIGURE 18 GREECE: POPULATION, 1998-2013
• (MILLIONS)
  • TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)
• THE GREEK HEALTHCARE SYSTEM
• Structure of the Healthcare System
• Healthcare Expenditures
  • TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005
• COMMON HEALTH PROBLEMS IN GREECE
• Pharmaceutical Pricing
  • TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN GREECE
  • FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%)
• Growth Drivers
• Barriers to Pharmaceutical Revenue Growth in Greece
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• Drivers and Restraints
• Over-the-Counter Medications
  • TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ MILLIONS)
  • TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN GREECE
• STATISTICS GREECE
• THE HELLENIC ASSOCIATION OF PHARMACEUTICAL COMPANIES (SFEE)
• EFEX, THE GREEK PROPRIETARY ASSOCIATION
• THE NETHERLANDS
• INTRODUCTION
  • TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
  • FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
• THE DUTCH HEALTHCARE SYSTEM
• Structure of the Healthcare System
• Healthcare Expenditures
  • TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005
• COMMON HEALTH PROBLEMS IN THE NETHERLANDS
• Drug Pricing
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN THE NETHERLANDS
  • FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• Drivers and Restraints
• Over-the-Counter Medications
  • TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ MILLIONS)
  • TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN THE NETHERLANDS
• STATISTICS NETHERLANDS
• NEFARMA, THE ASSOCIATION OF INNOVATE PHARMACEUTICALS IN THE NETHERLANDS
• BOGIN, THE ASSOCIATION OF DUTCH GENERIC MEDICATIONS INDUSTRY
• NEPROPHARM, THE NETHERLANDS ASSOCIATION OF OVER-THE-COUNTER PRODUCTS
• BELGIUM
• INTRODUCTION
  • TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
  • FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
• THE BELGIAN HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005
• COMMON HEALTH PROBLEMS IN BELGIUM
• DRUG PRICING
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN BELGIUM
  • FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ MILLIONS)
  • TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN BELGIUM
• STATISTICS BELGIUM
• PHARMA.BE, THE GENERAL ASSOCIATION OF THE MEDICINES INDUSTRY
• EUROGENERICS
• POLAND
• INTRODUCTION
  • TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)
  • FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)
• COMMON HEALTH PROBLEMS IN POLAND
• THE POLISH HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005
• DRUG PRICING
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ MILLIONS)
  • TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN POLAND
• POLISH CENTRAL STATISTICS OFFICE
• POLFARMED, POLISH CHAMBER OF PHARMACEUTICALS INDUSTRY AND MEDICAL DEVICES
• PASMI, THE POLISH ASSOCIATION OF THE SELF-MEDICATION INDUSTRY
• PORTUGAL
• INTRODUCTION
  • TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
  • FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
• THE PORTUGUESE HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005
• Pharmaceutical Pricing
  • FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%)
  • FIGURE 26 (CONTINUED)
• COMMON HEALTH PROBLEMS IN PORTUGAL
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ MILLIONS)
  • TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN PORTUGAL
• STATISTICS PORTUGAL
• APOGEN, PORTUGUESE ASSOCIATION OF GENERIC MEDICATIONS
• APIFARMA, THE ASSOCIATION OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY
• SWITZERLAND
• INTRODUCTION
  • TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
  • FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
• Common Health Problems in Switzerland
• THE SWISS HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005
• Pharmaceutical Environment and Pricing
• Pharmaceutical Environment …(Continued)
  • FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ MILLIONS)
  • TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN SWITZERLAND
• SWISS FEDERAL STATISTICS OFFICE
• COMPANY PROFILES
• NOVARTIS INTERNATIONAL AG
• SWEDEN
• INTRODUCTION
  • TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
  • FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
• HEALTH PROBLEMS AND HEALTHCARE IN SWEDEN
• The Healthcare System
  • TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005
• Pharmaceutical Pricing
  • FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)
• Health Problems in Sweden
  • TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF TOTAL MARKET, BY VALUE)
• MARKET SECTORS
• Branded Pharmaceuticals
  • TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN SWEDEN
• STATISTICS SWEDEN
• FGL, THE SWEDISH ASSOCIATION FOR GENERIC PHARMACEUTICALS
• AUSTRIA
• INTRODUCTION
  • TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
  • FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN AUSTRIA
• The Healthcare System
• Pharmaceutical Pricing
  • TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005
• Health Problems in Austria
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN AUSTRIA
• STATISTICS AUSTRIA
• PHARMIG, THE
• IGEPHA, THE AUSTRIAN SELF-MEDICATION INDUSTRY
• HUNGARY
• INTRODUCTION
  • TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
• HEALTH PROBLEMS AND HEALTHCARE IN HUNGARY
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in Hungary
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN HUNGARY
• HUNGARIAN CENTRAL STATISTICS OFFICE
• MAGYOSZ, THE HUNGARIAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION
• FINLAND
• INTRODUCTION
  • TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
  • TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
• HEALTH PROBLEMS AND HEALTHCARE IN FINLAND
• The Healthcare System
• PHARMACEUTICAL PRICING
• Health Problems in Finland
• MARKET SECTORS
  • TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)
• Branded Prescription Pharmaceuticals
  • TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN FINLAND
• STATISTICS FINLAND
• IMPORTANT ORGANIZATIONS IN EUROPE
• THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA)
• THE EUROPEAN GENERICS ASSOCIATION (EGA)
• THE ASSOCIATION OF THE EUROPEAN SELF-MEDICATION INDUSTRY (AESGP)

Chapter- 15: ASIA

• JAPAN
• INTRODUCTION
  • TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
  • TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
  • FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)
• THE JAPANESE HEALTHCARE SYSTEM
• Healthcare Expenditures in Japan
  • TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005
• Common Health Problems in Japan
  • TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005
• Cancer
  • TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005
• Alzheimer' s Disease and Related Dementias
• Obesity and Diabetes
• Cardiovascular Disease
• Smoking
• PHARMACEUTICAL PRICING
• Pharmaceutical Pricing (Continued)
• Pricing of Generic Drugs
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER MEDICATIONS IN JAPAN
  • TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
  • TABLE 203 LEADING OTC CATEGORIES, JAPAN
• IMPORTANT ORGANIZATIONS IN JAPAN
• STATISTICS BUREAU
• MINISTRY OF HEALTH, LABOUR, & WELFARE
• JPMA, JAPAN PHARMACEUTICAL MANUFACTURER' S ASSOCIATION
• JSMI, JAPANESE SELF-MEDICATION INDUSTRY
• COMPANY PROFILES
• ASTELLAS PHARMA
• SAWAI PHARMACEUTICAL COMPANY LTD.
• TAKEDA PHARMACEUTICAL COMPANY LTD.
• CHINA
• INTRODUCTION
  • TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)
  • TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN CHINA
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in China
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
• Over-the-Counter Medications
  • TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN CHINA
• NATIONAL BUREAU OF STATISTICS OF CHINA
• SOUTH KOREA
• INTRODUCTION
  • TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
  • TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN SOUTH KOREA
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in South Korea
  • TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003
• MARKET SECTORS
• Branded and Generic Prescription Pharmaceuticals
  • TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN SOUTH KOREA
• KOREAN NATIONAL STATISTICAL OFFICE
• AUSTRALIA
• INTRODUCTION
  • TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN AUSTRALIA
• The Healthcare System (Medicare)
• Pharmaceutical Pricing
• Health Problems in Australia
  • TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)
  • TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)
  • TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ MILLIONS)
  • TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)
• IMPORTANT ORGANIZATIONS IN AUSTRALIA
• AUSTRALIAN BUREAU OF STATISTICS
• DEPARTMENT OF INNOVATION, INDUSTRY, SCIENCE, AND RESEARCH
• MEDICINES AUSTRALIA
• INDIA
• INTRODUCTION
  • TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN INDIA
• Pharmaceutical Pricing
• HEALTH PROBLEMS IN INDIA
• MARKET SECTORS
• Overview
  • TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 ($ MILLIONS)
• Barriers to Growth in India
• Branded Prescription Pharmaceuticals
  • TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• Generics
• Over-the-Counter Medications
  • TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN INDIA
• MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION
• MINISTRY OF HEALTH
• IDMA, THE INDIAN DRUG MANUFACTURERS ASSOCIATION
• OPPI, THE ORGANISATION OF PHARMACEUTICAL PRODUCERS OF INDIA
• COMPANY PROFILES
• RANBAXY LABORATORIES, LTD
• CIPLA LTD.
• DR. REDDY' S LABORATORIES LTD.
• SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE
• PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES NOT COVERED IN DETAIL IN THIS REPORT
• PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES …
• PHARMACEUTICAL MARKETS…(CONTINUED)
• SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE

Global Pharmaceutical Markets published by BCC Research in May 1, 2008. This report consists of 328 pages and the price starts from US $ 5450.